Tumour growth was stunted by trametinib in N-Ras mutant (Q61K) neuroblastoma and EML4-ALK fusion-positive NSCLC xenografts, but not in the ALK-addicted neuroblastoma tumours [114]. The gene discussed is NRAS; the disease is neuroblastoma.